FOXO4-DRI Side Effects, Honestly
Unknown is the accurate answer, and it is a different answer from safe.
FOXO4-DRI side effects are unknown in humans. Not mild, not rare, not well tolerated: unknown, because no registered clinical trial has ever collected them. Any tidy side-effect list you find for this compound is describing something other than evidence.
Where the order actually gets placed
Ascension Peptides, FOXO4-DRI
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg, MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 2, 2026.
Unknown and safe are different findings
An established side-effect profile comes from structured observation: dose-ranging in a monitored group, systematic adverse-event collection, laboratory monitoring, and eventually post-marketing surveillance across a large population. Each stage produces information that could not have been predicted from the mechanism, which is exactly why the process exists rather than being replaced by reasoning.
None of it has happened here. FOXO4-DRI holds no approval from the FDA, the EMA or the MHRA and has never been administered to a person in a registered study.
Forum reports describe unverified material used in uncontrolled circumstances, often alongside several other compounds and a changed diet and training pattern. That makes them unusable as safety evidence even where the person writing is entirely sincere.
What the mechanism predicts
The compound disrupts binding between FOXO4 and p53, releasing p53 to trigger apoptosis in senescent cells. The concerns all follow from one question: what else does that affect?
Senescence is protective as well as pathological. When a cell accumulates DNA damage that could make it cancerous, senescence removes it from the replicative pool permanently. Eliminating senescent cells removes a population held in check for a reason.
Senescent cells assist repair. They appear transiently at wound sites and contribute to remodelling before being cleared naturally.
Selectivity is relative, not absolute. The peptide targets senescent cells preferentially rather than exclusively, and the margin has never been characterised in a human body. p53 is central to a great many normal processes.
These are not observed effects. They are the reasons a regulator would demand careful phase 1 work before anything else.
Where senolysis has already caused harm
The most useful safety information available concerns the strategy rather than this peptide, and it is not reassuring.
A 2023 study in Circulation examined senescent-cell clearance in pulmonary hypertension and found that eliminating senescent cells could promote the disease's development and progression. That is a direct demonstration that senolysis is context-dependent and can make a condition worse.
The 2017 work described its in-vivo dosing as being at a level where the peptide was well tolerated in the animals, which is a statement about mice under laboratory conditions in a short experiment, not a safety claim that transfers to people.
The risk that belongs to the batch, not the molecule
A separate category has nothing to do with mechanism and everything to do with what is in the vial.
Research-grade material is not manufactured under the controls governing injectable medicines. The relevant hazards are bacterial endotoxin, which survives sterilisation and provokes a strong inflammatory response, and microbial contamination. Both are properties of a specific production batch.
| Screen | Kovera batch 55-05260628 | MZ Biolabs lot 55-01260229 | | --- | --- | --- | | Purity | 99.411% | 99.97% | | Net content | 11.41 mg | 8.30 mg | | Endotoxin | Pass, at or below 0.5 EU/mL | Not performed | | Microbial sterility | No growth | Not performed |
Read the bottom two rows. A claim that this product is endotoxin tested describes one lot and not the other. Testing scope is a batch property, so the only way to know which applies to your vial is to read the certificate matching its lot number rather than the file linked from the product page.
Handling introduces contamination risk independent of manufacturing, which is why solvent choice and storage discipline matter for anything entered more than once.